In a recent study, researchers find reasons why a significant number of US adults are at risk of unintentionally overdosing on over-the-counter pain medications.
A new study suggests reasons why a significant number of US adults are at risk of unintentionally overdosing on over-the-counter (OTC) pain medications.
The study, published in the Online First edition of the Journal of General Internal Medicine, was led by Michael S. Wolf, MD, with the Feinberg School of Medicine at Northwestern University, Chicago.
Dr Wolf and colleagues surveyed 500 adult patients of outpatient general medicine clinics between September 2009 and March 2011. Almost half (45.6%) of the adults demonstrated that they would overdose by taking 2 acetaminophen-containing products. Overall, 23.8% of patients demonstrated that they would overdose on a single OTC acetaminophen medication by exceeding a dose of 4 grams in a 24-hour period.
The researchers found that the overdoses were linked to limited literacy and, independently, heavy acetaminophen use over the past 6 months.
While other studies have demonstrated OTC acetaminophen abuse, researchers found some of the root causes of the problem. For example, when patients were asked to dose out single OTC medications, they were more likely to exceed the maximum daily dose of 4 grams with the 1,000 mg-dose product and least likely with the 500 mg-dose medications. “This could either be attributed to the product’s higher dosage….more ambiguous directions, or simply instructions that allow you to exceed the maximum daily dose by too many doses per day,” the researchers wrote.
Rates of “double-dipping” (ie, taking 2 acetaminophen-containing products) were highest between a pain-reliever medication and nighttime-pain reliever, followed by pain reliever and cough/cold medication together, and then the combination of a sinus medication and a nighttime-pain reliever. “Even though the active ingredients in each product are stated on the package and bottle labels, it could be that the symptom relief advertised on the product suggests to consumers that the products contain different medicine, and that dual use might be safe,” the researchers wrote.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More